merrimack pharmaceuticals in
(MACK:NASDAQ GS)

Executive Profile*

Background*

Mr. James H. Quigley, Jim served as the Global Chief Executive Officer of Deloitte Touche Tohmatsu of Deloitte & Touche LLP from June 1, 2007 to June 1, 2011. Previously, Mr. Quigley served as the Chief Executive Officer of Deloitte & Touche USA LLP (D&T USA) since June 2003. He served as the Vice Chairman of D&T USA and Regional Managing Partner of D&T USA's Northeast practice, with responsibility for service to companies in the metropolitan region of New York, New ... Jersey, and Connecticut. He also served as Chief Executive Officer of Deloitte & Touche LLP. Mr. Quigley serves as a Director of Deloitte & Touche LLP. He serves as Trustee of Financial Accounting Foundation Inc. and Central Park Conservancy, Inc. He has been a Director of Merrimack Pharmaceuticals, Inc. since July 12, 2012. He has been an Independent Director of Hess Corporation since May 16, 2013. He serves as a Director of Deloitte Touche Tohmatsu (DTT) and Deloitte & Touche USA LLP (D&T USA). Mr. Quigley served as a Director of The Partnership for New York City, Inc. Catalyst Inc., US Chamber of Commerce and NYC2012 Inc. He served as Director of Business Council of New York State Inc. In 2012, Mr. Quigley was named Trustee of the International Financial Reporting Standards (IFRS) Foundation, the oversight body of the International Accounting Standards Board (IASB). He received his Bachelor of Science degree from Utah State University as well as an honorary degree of Doctor of Business. He also was awarded an Honorary Degree of Doctor of Commercial Science from Bentley College in Waltham, Massachusetts.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
MACK:US	$6.39 USD	+0.01

COMPETITOR COMPENSATION